CL2021000083A1 - Composición farmacéutica en la forma de un comprimido masticable de diosmina o de una fracción flavonoica. - Google Patents
Composición farmacéutica en la forma de un comprimido masticable de diosmina o de una fracción flavonoica.Info
- Publication number
- CL2021000083A1 CL2021000083A1 CL2021000083A CL2021000083A CL2021000083A1 CL 2021000083 A1 CL2021000083 A1 CL 2021000083A1 CL 2021000083 A CL2021000083 A CL 2021000083A CL 2021000083 A CL2021000083 A CL 2021000083A CL 2021000083 A1 CL2021000083 A1 CL 2021000083A1
- Authority
- CL
- Chile
- Prior art keywords
- pharmaceutical composition
- diosmin
- chewable tablet
- flavonoic fraction
- flavonoic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se describe una composición farmacéutica en la forma de un comprimido masticable fuertemente dosificado en diosmina micronizada. Esta composición farmacéutica comprende entre un porcentaje de diosmina micronizada entre el 20% y el 80% de la masa total de la composición farmacéutica. Esta composición farmacéutica se utiliza en el tratamiento de la insuficiencia venosa y de la crisis hemorroidal.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1856769A FR3083980B1 (fr) | 2018-07-20 | 2018-07-20 | Composition pharmaceutique sous la forme d'un comprime a croquer de diosmine ou d'une fraction flavonoique |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021000083A1 true CL2021000083A1 (es) | 2021-07-30 |
Family
ID=65243687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021000083A CL2021000083A1 (es) | 2018-07-20 | 2021-01-12 | Composición farmacéutica en la forma de un comprimido masticable de diosmina o de una fracción flavonoica. |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP3823588A1 (es) |
KR (1) | KR20210034036A (es) |
CN (1) | CN112423735A (es) |
AR (1) | AR117612A1 (es) |
AU (1) | AU2019306315B2 (es) |
BR (1) | BR112021000440A2 (es) |
CA (1) | CA3106495C (es) |
CL (1) | CL2021000083A1 (es) |
CO (1) | CO2021000115A2 (es) |
CR (1) | CR20210023A (es) |
EA (1) | EA202190269A1 (es) |
EC (1) | ECSP21001232A (es) |
FR (1) | FR3083980B1 (es) |
JO (1) | JOP20210003A1 (es) |
MA (1) | MA53159A (es) |
MX (1) | MX2021000763A (es) |
NI (1) | NI202100002A (es) |
PE (1) | PE20210929A1 (es) |
PH (1) | PH12021550037A1 (es) |
SG (1) | SG11202100181YA (es) |
TW (1) | TWI831808B (es) |
WO (1) | WO2020016408A1 (es) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2661610B1 (fr) * | 1990-05-02 | 1994-09-30 | Rhone Poulenc Sante | Nouvelle forme lyophilisee de la diosmine et sa preparation. |
FR2661830B1 (fr) * | 1990-05-11 | 1992-09-04 | Corbiere Jerome | Nouvelle compositions pharmaceutiques a base de flavonoside. |
FR2726469B1 (fr) * | 1994-11-08 | 1996-12-13 | Adir | Composition pharmaceutique pour l'administration orale de flavonoides |
FR2845597B1 (fr) * | 2002-10-11 | 2005-03-11 | Innothera Lab Sa | Formulation orale seche contenant de la diosmine sous forme pharmaceutique de comprime a croquer |
ITMI20050517A1 (it) | 2005-03-30 | 2006-09-30 | Therapicon Srl | Composizione farmaceutica di una tipica frazione microcristallina di flavonoidi |
FR2999934B1 (fr) * | 2012-12-21 | 2015-02-20 | Servier Lab | Composition pharmaceutique sous la forme d'une suspension orale comprenant une fraction flavonoique et de la gomme xanthane |
-
2018
- 2018-07-20 FR FR1856769A patent/FR3083980B1/fr active Active
-
2019
- 2019-07-19 CR CR20210023A patent/CR20210023A/es unknown
- 2019-07-19 EA EA202190269A patent/EA202190269A1/ru unknown
- 2019-07-19 AR ARP190102031A patent/AR117612A1/es unknown
- 2019-07-19 MA MA053159A patent/MA53159A/fr unknown
- 2019-07-19 EP EP19742363.5A patent/EP3823588A1/fr active Pending
- 2019-07-19 JO JOP/2021/0003A patent/JOP20210003A1/ar unknown
- 2019-07-19 CN CN201980047436.7A patent/CN112423735A/zh active Pending
- 2019-07-19 PE PE2021000077A patent/PE20210929A1/es unknown
- 2019-07-19 SG SG11202100181YA patent/SG11202100181YA/en unknown
- 2019-07-19 CA CA3106495A patent/CA3106495C/fr active Active
- 2019-07-19 KR KR1020217004706A patent/KR20210034036A/ko active Search and Examination
- 2019-07-19 AU AU2019306315A patent/AU2019306315B2/en active Active
- 2019-07-19 MX MX2021000763A patent/MX2021000763A/es unknown
- 2019-07-19 TW TW108125532A patent/TWI831808B/zh active
- 2019-07-19 WO PCT/EP2019/069498 patent/WO2020016408A1/fr unknown
- 2019-07-19 BR BR112021000440-8A patent/BR112021000440A2/pt unknown
-
2021
- 2021-01-07 PH PH12021550037A patent/PH12021550037A1/en unknown
- 2021-01-08 CO CONC2021/0000115A patent/CO2021000115A2/es unknown
- 2021-01-08 NI NI202100002A patent/NI202100002A/es unknown
- 2021-01-08 EC ECSENADI20211232A patent/ECSP21001232A/es unknown
- 2021-01-12 CL CL2021000083A patent/CL2021000083A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
MA53159A (fr) | 2021-05-26 |
NI202100002A (es) | 2021-06-22 |
PH12021550037A1 (en) | 2021-09-27 |
CN112423735A (zh) | 2021-02-26 |
KR20210034036A (ko) | 2021-03-29 |
AU2019306315A1 (en) | 2021-02-11 |
WO2020016408A1 (fr) | 2020-01-23 |
JOP20210003A1 (ar) | 2021-01-10 |
CO2021000115A2 (es) | 2021-01-29 |
EA202190269A1 (ru) | 2021-06-15 |
FR3083980B1 (fr) | 2021-04-16 |
ECSP21001232A (es) | 2021-02-26 |
SG11202100181YA (en) | 2021-02-25 |
TW202019439A (zh) | 2020-06-01 |
EP3823588A1 (fr) | 2021-05-26 |
MX2021000763A (es) | 2021-03-29 |
PE20210929A1 (es) | 2021-05-19 |
AU2019306315B2 (en) | 2023-03-09 |
CR20210023A (es) | 2021-02-22 |
TWI831808B (zh) | 2024-02-11 |
CA3106495C (fr) | 2023-08-08 |
CA3106495A1 (fr) | 2020-01-23 |
FR3083980A1 (fr) | 2020-01-24 |
AR117612A1 (es) | 2021-08-18 |
BR112021000440A2 (pt) | 2021-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR057181A1 (es) | Nueva forma de dosificacion de combinacion | |
MX2020009758A (es) | Producto combinado de inhibidor de bcl-2 o inhibidor dual de bcl-2/bcl-xl e inhibidor de btk y uso de este en la prevencion y/o tratamiento de enfermedades. | |
CL2012000446A1 (es) | Uso de una formulación vesicular tópica que comprende uno o más fosfolípidos y uno o más tensoactivos en una razón molar de 1:1 a 25:1 de fosfolípidos a tensoactivos, para el tratamiento de trastornos dermatosos inflamatorios. | |
CO5640087A2 (es) | Composiciones de farmacos anti-inflamatorios no esteroideos descongestionantes y anti-histaminicos | |
AR048833A1 (es) | Procedimiento para el tratamiento de trastornos premenstruales y otros trastornos sexuales femeninos | |
CL2019000485A1 (es) | Uso de pridopidina para el tratamiento de la disminución funcional. | |
PE20211069A1 (es) | Composicion que comprende 5'-metilselenoadenosina, selenoadenosil-l-homocisteina y gama glutamil-metilselenocisteina | |
NO20062198L (no) | Bradykinin B1 reseptorantagonister | |
CL2018001686A1 (es) | Métodos y composiciones particularmente para el tratamiento del trastorno por déficit de atención (divisional solicitud 201701026) | |
ES2572157T3 (es) | Composiciones en forma de partículas para la administración de fármacos poco solubles | |
CL2015002304A1 (es) | Formas del metil {4,6-diamino-2- [1- (2-fluorobencil)-1h-pirazolo [3,4-b] piridino-3-il] pirimidino-5-il} metil carbamato | |
PA8809601A1 (es) | Combinación anti-retroviral | |
UY35293A (es) | Isotiazoles sustituidos con amino | |
GT200500266A (es) | Nuevos derivados de pirimidina y su uso | |
AR048587A1 (es) | Composiciones quimicamente estables de 4-hidroxitamoxifeno | |
CO6210818A2 (es) | Composiciones que comprenden quitosanos para el tratamiento de enfermedades inflamatorias de las uñas | |
AR106505A1 (es) | Tratamiento de la oligo-ovulación relacionada con esteatosis hepática | |
UY28517A1 (es) | Nueva combinación | |
CO6280488A2 (es) | Combinacion farmaceutica | |
HK1114769A1 (en) | Antitumor combinations containing a vegf inhibitor and 5fu or one of its derivative | |
CL2021000083A1 (es) | Composición farmacéutica en la forma de un comprimido masticable de diosmina o de una fracción flavonoica. | |
PE20211199A1 (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
AR085399A1 (es) | Combinacion antitumoral que comprende cabazitaxel y cisplatino | |
AR104721A1 (es) | Fragmento fab anti-ngf humano | |
MX2020003786A (es) | Composiciones orales para el tratamiento de reflujo gastroesofagico. |